Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
(-)
News
(42)
Filter by content year
(-)
2022
(42)
Filter by form group
Filter by category
(-)
Clinical
(42)
Collaborators
(37)
All
(34)
Other
(17)
Science
(10)
Events
(2)
Filter by category
Search
News
Pfizer und BioNTech treiben COVID-19-Impfstoffstrategie weiter voran: neue klinische Studie mit Impfstoffkandidaten der nächsten Generation mit verbessertem Design des Spike-Proteins begonnen
News
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
News
Pfizer und BioNTech reichen Antrag für Notfallzulassung eines angepassten bivalenten COVID-19-Impfstoffs für Omikron-Varianten BA.4/BA.5 bei der FDA ein
News
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
News
Pfizer und BioNTech geben Update zur Wirksamkeit ihres COVID-19-Impfstoffs bei Kindern von 6 Monaten bis 4 Jahren
News
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
News
BioNTech präsentiert auf ESMO-Kongress weitere ermutigende Daten aus Phase-1/2-Studie mit CAR-T-Programm BNT211 in schwer zu behandelnden soliden Tumoren
News
BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO
News
Pfizer und BioNTech geben frühe positive Daten aus klinischer Studie mit an Omikron BA.4/BA.5 angepasstem bivalenten Auffrischungsimpfstoff bei Personen ab 18 Jahren bekannt
News
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
Pagination
Page 1
Next page
››